Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Bacterial Infections
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Tygacil
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections Complicated intra-abdominal infections (cIAI) Tygacil should be used only in situations where other alternative antibiotics are not suitable. Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.
View on EMAVaccines, Pneumococcal
Diabetes Mellitus
Renal Transplantation
Major Depressive Disorder
Complicated Intra-abdominal Infections